Gorjan Hrustanovic

Gorjan Hrustanovic is an accomplished professional with a strong educational background in Biomedical Sciences, Cancer Biology, and Cell Signaling.

He holds a Ph.D. in Biomedical Sciences with a focus on Cancer Biology & Cell Signaling from the esteemed University of California, San Francisco. Prior to this, he pursued his undergraduate studies at UC San Diego, where he obtained dual B.S. degrees in Molecular Biology and Management Science, showcasing his diverse academic interests and skills.

Throughout his career, Gorjan Hrustanovic has held key roles in several prominent organizations within the biotechnology and pharmaceutical sectors. He has served on the Board of Directors at reputable companies such as Nimbus Therapeutics, Plexium, Kymera Therapeutics, Olema Oncology, and Rain Therapeutics, demonstrating his expertise in guiding strategic decisions and contributing to the growth of innovative healthcare ventures.

With a solid foundation in the field of biotechnology, Gorjan Hrustanovic also leveraged his academic achievements and industry experience as a Managing Director at Biotechnology Value Fund (BVF Partners L.P.), where he likely played a crucial role in investment strategies and portfolio management within the biotech space.

Prior to his executive roles, Gorjan Hrustanovic enriched his scientific acumen during his Ph.D. studies at UCSF, honing his research skills and expanding his knowledge in the realm of Biomedical Sciences.

Overall, Gorjan Hrustanovic's impressive academic journey, coupled with his noteworthy contributions to various organizations and his tenure as a Managing Director, underscores his expertise and leadership in the biotechnology industry.